Risk scoring in the assessment of cardiovascular risk

被引:39
作者
Beswick, Andrew
Brindle, Peter
机构
[1] Univ Bristol, MRC Hlth Serv Res Collaborat, Bristol BS8 2PR, Avon, England
[2] Univ Bristol, Dept Social Med, Bristol, Avon, England
关键词
cardiovascular disease; cardiovascular risk; risk scoring;
D O I
10.1097/01.mol.0000236362.56216.44
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Purpose of review Cardiovascular risk scoring is incorporated in guidelines and recommended for targeting preventive treatment. Evidence is required on the most appropriate method, its accuracy in a given population, and its effectiveness in favourably influencing clinical behaviour and health outcomes. Recent findings Recent risk scores address inaccuracies that arise when methods are transferred between populations, and specific methods and recalibrations are described for use in low-risk populations. Ethnic and social differences in risk are also recognized in the context of cardiovascular risk scoring. More sensitive measures of known-risk factors and numerous emerging risk factors are-reported and new statistical methods and sources of data suggested. Little emphasis has been placed on evaluation of the clinical effectiveness of cardiovascular risk scores. Education in cardiovascular risk assessment may help improve uptake of methods by healthcare professionals. Summary Numerous risk scoring methods are available to the healthcare professional but use is patchy. Accuracy varies between populations and methods have been developed to compensate for some of this variability. If risk scoring methods are to be widely used in general practice, evidence is required on both the accuracy of methods in appropriate populations and their effectiveness in improving health outcomes.
引用
收藏
页码:375 / 386
页数:12
相关论文
共 121 条
[31]   B-type natriuretic peptide as an alternative way of assessing total cardiovascular risk in patients with diabetes mellitus [J].
Dawson, A ;
Jeyaseelan, S ;
Morris, AD ;
Struthers, AD .
AMERICAN JOURNAL OF CARDIOLOGY, 2005, 96 (07) :933-934
[32]   European guidelines on cardiovascular disease prevention in clinical practice -: Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice [J].
De Backer, G ;
Ambrosioni, E ;
Borch-Johnsen, K ;
Brotons, C ;
Cifkova, R ;
Dallongeville, J ;
Ebrahim, S ;
Faergeman, O ;
Graham, I ;
Mancia, G ;
Cats, VM ;
Orth-Gomér, K ;
Perk, J ;
Pyörälä, K ;
Rodicio, JL ;
Sans, S ;
Sansoy, V ;
Sechtem, U ;
Silber, S ;
Thomsen, T ;
Wood, D .
EUROPEAN HEART JOURNAL, 2003, 24 (17) :1601-1610
[33]   Randomised evaluation of a specific training of general practitioners in cardiovascular prevention [J].
De Muylder, R ;
Tonglet, R ;
Nackers, F ;
Boland, B .
ACTA CARDIOLOGICA, 2005, 60 (02) :199-205
[34]   For and against - Aspirin for everyone older than 50? [J].
Elwood, P ;
Morgan, G ;
Brown, G ;
Pickering, J ;
Baigent, C .
BMJ-BRITISH MEDICAL JOURNAL, 2005, 330 (7505) :1440-1443
[35]   Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations?: The PRIME Study [J].
Empana, JP ;
Ducimetière, P ;
Arveiler, D ;
Ferrières, J ;
Evans, A ;
Ruidavets, JB ;
Haas, B ;
Yarnell, J ;
Bingham, A ;
Amouyel, P ;
Dallongeville, J .
EUROPEAN HEART JOURNAL, 2003, 24 (21) :1903-1911
[36]  
*ER RES GROUP, 1991, EUROPEAN HEART J, V12, P291
[37]   The polypill and cardiovascular disease - May be appropriate for secondary, but perhaps notfor primary prevention [J].
Fahey, T ;
Brindle, P ;
Ebrahim, S .
BMJ-BRITISH MEDICAL JOURNAL, 2005, 330 (7499) :1035-1036
[38]   Prediction of coronary events in a low incidence population. Assessing accuracy of the CUORE Cohort Study prediction equation [J].
Ferrario, M ;
Chiodini, P ;
Chambless, LE ;
Cesana, G ;
Vanuzzo, D ;
Panico, S ;
Sega, R ;
Pilotto, L ;
Palmieri, L ;
Giampaoli, S .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2005, 34 (02) :413-421
[39]  
FODOR G, 2000, CMAJ, V10, P1441
[40]  
FORD DR, 2001, CORON HEART CARE, V5, P4